CTLA4 and neoplasm: Based on the observed increase in [64Cu]NOTA-CD8a tumor-to-heart ratio of the XRT + anti-CTLA-4 group, the [64Cu]NOTA-CD8a tumor-to-heart ratio was plotted for control, TNRs, and TRs (Fig. 3c).